🇺🇸 FDA
Pipeline program

Therapeutic approach of repeated transient blood-brain barrier opening in amyotrophic lateral sclerosis

APHP230845

Phase 2 other active

Quick answer

Therapeutic approach of repeated transient blood-brain barrier opening in amyotrophic lateral sclerosis for Amyotrophic lateral Sclerosis is a Phase 2 program (other) at Pari Pharma GmbH with 1 ClinicalTrials.gov record(s).

Program details

Company
Pari Pharma GmbH
Indication
Amyotrophic lateral Sclerosis
Phase
Phase 2
Modality
other
Status
active

Clinical trials